Vaxart Future Growth
Future criteria checks 5/6
Vaxart is forecast to grow earnings and revenue by 76% and 74.8% per annum respectively while EPS is expected to grow by 70.7% per annum.
Key information
76.0%
Earnings growth rate
70.7%
EPS growth rate
| Biotechs earnings growth | 43.0% |
| Revenue growth rate | 74.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 170 | -20 | -142 | -187 | 5 |
| 12/31/2023 | 56 | -87 | -122 | -141 | 5 |
| 12/31/2022 | 1 | -105 | -107 | -102 | 4 |
| 3/31/2022 | 0 | -80 | -74 | -68 | N/A |
| 12/31/2021 | 1 | -70 | -65 | -60 | N/A |
| 9/30/2021 | 1 | -64 | -60 | -55 | N/A |
| 6/30/2021 | 1 | -54 | -54 | -50 | N/A |
| 3/31/2021 | 2 | -47 | -39 | -37 | N/A |
| 12/31/2020 | 4 | -32 | -25 | -24 | N/A |
| 9/30/2020 | 8 | -25 | -17 | -17 | N/A |
| 6/30/2020 | 8 | -22 | -12 | -12 | N/A |
| 3/31/2020 | 7 | -19 | -12 | -12 | N/A |
| 12/31/2019 | 10 | -19 | -14 | -13 | N/A |
| 9/30/2019 | 8 | -17 | -16 | -15 | N/A |
| 6/30/2019 | 8 | -18 | -17 | -16 | N/A |
| 3/31/2019 | 8 | -22 | -10 | -9 | N/A |
| 12/31/2018 | 4 | -18 | -15 | -15 | N/A |
| 9/30/2018 | 3 | -15 | -12 | -11 | N/A |
| 6/30/2018 | 4 | -12 | -8 | -8 | N/A |
| 3/31/2018 | 5 | -7 | -17 | -16 | N/A |
| 12/31/2017 | 6 | -12 | -10 | -10 | N/A |
| 9/30/2017 | 9 | -16 | -9 | -9 | N/A |
| 12/31/2016 | 8 | -19 | -12 | -12 | N/A |
| 12/31/2015 | 0 | -22 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NB11 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Earnings vs Market: NB11 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NB11 is expected to become profitable in the next 3 years.
Revenue vs Market: NB11's revenue (74.8% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: NB11's revenue (74.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NB11's Return on Equity is forecast to be high in 3 years time